EP1670439A2 - Solid dosage form comprising desmopressin - Google Patents

Solid dosage form comprising desmopressin

Info

Publication number
EP1670439A2
EP1670439A2 EP04730504A EP04730504A EP1670439A2 EP 1670439 A2 EP1670439 A2 EP 1670439A2 EP 04730504 A EP04730504 A EP 04730504A EP 04730504 A EP04730504 A EP 04730504A EP 1670439 A2 EP1670439 A2 EP 1670439A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
particle size
dosage form
solid dosage
average particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04730504A
Other languages
German (de)
French (fr)
Inventor
Hàkan LOMRYD
Helena Nicklasson
Lars-Erik Olsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32981781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1670439(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring BV filed Critical Ferring BV
Priority to EP04730504A priority Critical patent/EP1670439A2/en
Publication of EP1670439A2 publication Critical patent/EP1670439A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Definitions

  • the present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof .
  • Desmopressin also known as dDAVP, is the therapeutically active ingredient (as its acetate salt) in the pharmaceutical product Minirin ® , which is marketed inter alia as a nasal spray and a tablet formulation.
  • Desmopressin is primarily used in the treatment of primary nocturnal enuresis, i.e. bedwetting, in children, but it is approved also for the treatment of nocturia and diabetes insipidus.
  • the first market introduction of the tablet formulation was in Sweden in 1987.
  • a solid dosage form such as a tablet formulation is typically manufactured by compression of a suitable granulate to the desired solid dosage form, where the granulate is composed of the required constituents as a mixture of solid particles.
  • Typical such particles are the therapeutically active ingredient, various excipients (fillers) , disintegrating agents, lubricants and binders, optionally together e . g. with flavoring agent, preservative and/or colorant.
  • the commercially available Minirin ® tablet is prepared according to this general protocol, and the tablet was first disclosed as set forth in the patent US 5 047 398, the teachings of which are incorporated herein by reference. For a comprehensive overview of pharmaceutical tablet manufacturing, see n Tableting" (by N.A.
  • the Minirin ® tablet that is currently marketed, and thus produced in industrial scale, consists of the thera- Implantically active ingredient desmopressin together with potato starch and lactose as excipients, and a suitable amount of binder and lubricant, respectively.
  • the present invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein at least one of said excipient, diluent and carrier is a substance selected from a monosaccharide, disaccharide, oligosac- charide and a polysaccharide, wherein the said substance has an average particle size in the range of from 60 to 1 000 ⁇ m. In those embodiments where there is a mixture of at least two of the aforementioned types of saccharides, at least one of them must accordingly be within the specified particle size range of the present invention.
  • excipient in many cases the terms excipient, diluent and carrier can be used interchangeably, and they may even refer to one and the same substance, or to a mixture of similar such substances. The proper use and understanding of these terms is self-explanatory and lies well within the ability of a person skilled in the art of pharmaceutical formulation.
  • the pharmaceutical composition according to the present invention may optionally comprise at least one additive selected from a disintegrating agent, lubricant, binder, flavoring agent, preservative, colorant and a mixture thereof. Where considered suitable also other additives may be included.
  • a disintegrating agent e . g. magnesium stearate
  • binders e . g. Kollidon® 25, BASF
  • flavoring agents e . g. magnesium stearate
  • binders e . g. Kollidon® 25, BASF
  • flavoring agents, preservatives and colorants e. g. Kollidon® 25, BASF
  • suitable mixtures thereof as well as any other conventional additive that may be considered by a person skilled in the art practising the present invention, can be found in "Handbook of Pharmaceutical Excipients" ; Ed. A.H. Kibbe, 3 rd Ed. , American Pharmaceutical Association, USA and
  • the expression oligosaccharide relates to a chain, with any degree of branching, of from three to ten monosaccharide units linked via glycoside bonds.
  • the expression polysaccharide relates to a chain, with any degree of branching, of at least eleven monosaccharide units linked via glycoside bonds.
  • Synthetically modified derivatives and analogues of naturally occurring saccharides are also possible to use in the practising of the present invention.
  • the lactose particles In the marketed tablet resulting from the hitherto used manufacturing process, the lactose particles (Pharmatose 150M provided by DMV, the Netherlands) have an average size of about 50 ⁇ m, as determined by an air jet sieve (provided by Alpine GmbH, DE) .
  • That particle size does not provide a granulate that allows a compressing speed exceeding about 170 000 tablets per hour (h) .
  • the process according to the present invention allows a compressing speed of up to about 250 000 tablets/h with the desired tablet quality and retained low level of wear on the tabletting machinery.
  • said average particle size is in the range of from 70 to 500 ⁇ m. In another preferred embodiment, said average particle size is in the range of from 75 to 350 ⁇ m. In yet another preferred embodiment, said average particle size is in the range of from 100 to 200 ⁇ m. In a further preferred embodiment, said average particle size is in the range of from 120 to 180 ⁇ m. In the most preferred embodiment of the present invention, said average particle size is 140 ⁇ m (as measured by an air jet sieve) .
  • the lactose particles sold as Pharmatose DCL 15, marketed by DMV in the Netherlands, are of this most preferred average particle size.
  • the particle size distribution of Pharmatose DCL 15 is that essentially all particles have a size below 500 ⁇ m, whereas approximately 72% of the particles have a size of from 75 to 350 ⁇ m.
  • said substance is a disaccharide, preferably lactose, and more preferably lactose- ⁇ -monohydrate .
  • starch is preferred, and of the many available starches, potato starch is the most preferred.
  • potato starches mention can be made of Pharma M20, Pharma M14 (provided by KMC, DK) and AmylSolVat (provided by Lyckeby Starkelse AB, SE) .
  • both said disaccharide and polysaccharide are present in the pharmaceutical composition.
  • the weight ratio between said disaccharide and polysaccharide is typically from 100:1 to 1:100, preferably from 10:1 to 1:10, and more preferably from 2:1 to 1:2.
  • the total combined amount of said excipient, diluent and carrier is usually from 5 to 99, preferably from 50 to 99, percent by weight of the pharmaceutical composition, the balance up to 100% being the therapeutically active ingredient optionally together with the aforementioned additives, where the latter is preferably lubricant and binder.
  • the pharmaceutical composition as a solid dosage form according to the present invention is typically a perorally available tablet. As an alternative non- limiting embodiment, the said tablet may be adapted for oral, including buccal and/or sublingual, administration.
  • the composition typically comprises desmopressin acetate in an amount of from 20 to 600 ⁇ g per unit of solid dosage form.
  • a typical tablet containing 100 ⁇ g of desmopressin acetate is white, convex and oval (6.7 x 9.5 mm) with a thickness of 3-4 mm and a weight of 200 mg.
  • a tablet containing 200 ⁇ g of desmopressin acetate is white, round (8 mm diameter) and convex with a thickness of 3-4 mm and a weight of 200 mg.
  • a further aspect of the present invention relates to a method for the manufacturing of a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient, wherein said method comprises the steps of: i) mixing desmopressin and an excipient, diluent or carrier, or mixture thereof, optionally in the presence of a wetting agent, wherein at least one of said excipient, diluent and carrier is a substance selected from a monosaccharide, disaccharide, oligosaccharide and a polysaccharide, wherein said substance has an average particle size in the range of from 60 to 1 000 ⁇ m; ii) subjecting the resulting mixture to formation of a granulate, optionally in the presence of a wetting agent, suitable for compression into said solid dosage form; iii) optionally performing said mixing and/or formation of a granulate in the presence of at least one additive selected from a disintegrating agent,
  • a granulate suitable for compression into tablets typically has an average granulate size of at least about 100 ⁇ m. Discrete granules with a size above 2 mm are usually not transferred to the subsequent compressing step.
  • the aforementioned equipment in general also provides drying of the prepared granules.
  • an upper limit for said average particle size are 900, 800, 700 and 600 ⁇ m.
  • said average particle size is in the range of from 70 to 500 ⁇ m.
  • said average particle size is in the range of from 75 to 350 ⁇ m.
  • said average particle size is in the range of from 100 to 200 ⁇ m.
  • said average particle size is in the range of from 120 to 180 ⁇ m.
  • said average particle size is 140 ⁇ m.
  • the lactose particles sold as Pharmatose DCL 15, marketed by DMV in the Netherlands, are of this most preferred average particle size.
  • Other possible embodiments of the present method may involve the aforementioned variants of Pharmatose DCL (vide supra) .
  • said substance is a disaccharide, preferably lactose, and more preferably lactose- ⁇ -monohydrate.
  • Said monosaccharide may also be D- mannitol, D-sorbitol or xylitol or a mixture thereof.
  • Said polysaccharide is preferably a starch, and more preferably potato starch.
  • Preferred particular potato starches are the same as those mentioned above.
  • the manufactured solid dosage form is typically a perorally available tablet. Where desired, it may also be in a form and/or composition adapted for oromucosal administration. Preferred examples of the latter are buccal and/or sublingual administration.
  • tablet compressing equipment suitable for the practising of the present invention are rotary presses provided by Elizabeth-Hata International, US (HT series) , Courtoy NV, BE (R090F, R100M, R190FT, R290FT, R292F and R233 series) , Vector Corp., US (2000, 200 and Magna series), Fette
  • steps of mixing and formation of granulate are performed in a single integrated machinery that is adapted for such a "one-pot", i . e . combined, process.
  • integrated machinery alternatively denoted one-pot (single pot) equipment, is the FT series, provided by Forberg A/S, Norway.
  • said wetting agent is selected from water and a mixture of water and an alcohol, preferably ethanol .
  • a water/ethanol 1:3 mixture is typically used, albeit many other combinations are also possible.
  • said resulting mixture is subjected to formation of a granulate with an average granulate size of a least 100 ⁇ m, preferably in the range of from 100 ⁇ m to 2 mm.
  • both said disaccharide and polysaccharide are present in the mixing step.
  • the weight ratio between said disaccharide and polysaccharide is then typically from 100:1 to 1:100, preferably from 10:1 to 1:10, and more preferably from 2:1 to 1:2.
  • the method is preferably performed in such a manner that the total combined amount of said excipient, diluent and carrier is from 5 to 99, preferably from 50 to 99, percent by weight of the pharmaceutical composition.
  • desmopressin acetate is used and mixed with said excipient, diluent and/or carrier in an amount that eventually provides from 20 to 600 ⁇ g of desmopressin acetate per unit of solid dosage form (see above and the experimental part for examples of a tablet) .
  • the present invention also relates to a pharmaceutical composition as a solid dosage form that is obtainable by the novel method as defined above, both in general and as outlined in the specific embodiments .
  • Example 1 Preparation of solid dosage form of dDAVP Desmopressin acetate (100 or 200 g; provided by PolyPeptide Laboratories AB, SE) , polyvinyl pyrrolidone (PVP) as binder (1,84 kg; Kollidon® 25 provided by BASF GmbH, DE) and granulation liquid (water/ethanol 1:3 mixture) are combined in a vessel and mixed at room temperature until a clear solution is achieved.
  • the potato starch (77 kg, average particle size about 40-50 ⁇ m according to laser diffraction measurements;
  • AmylSolVat provided by Lyckeby Starkelse AB, SE is weighed and sieved through a 2 mm sieve. Lactose (120 kg, DCL 15 provided by DMV NV, NL; see above for the details of this product) is weighed and loaded together with the starch into a single pot mixer (FT-350; provided by Forberg A/S, NO) and mixed therein. The granulation liquid solution is then sprayed onto the powder mixture, after which the moist granulate is dried with warm air (150°C) , all with continued mixing. The dried granulate is then sieved (2 mm) and transferred to a double cone mixer.
  • FT-350 provided by Forberg A/S, NO
  • Magnesium stearate (max 1.0 kg; provided by Peter Greven NV, NL) is then weighed in, sieved (1 mm) and transferred to the double cone mixer for final mixing. Tablets are then compressed from the resulting mixture by using a conventional rotary tablet compression machine (Kilian S-250) , whereby a compressing speed of about 250 000 tablets/h is attainable with adequate tablet quality and low machine wear.
  • a tablet of adequate quality has a smooth surface without scratches or chipped edges, and it shows no tendencies to lamination (so- called capping) .
  • the process is typically adapted to provide a tablet containing 100 or 200 ⁇ g of desmopressin acetate with the aforementioned appearance, dimension and weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein at least one of said excipient, diluent and carrier is a substance selected from a monosaccharide, disaccharide, oligosaccharide and a polysaccharide, wherein the said substance has an average particle size in the range of from 60 to 1 000 mu m. A method according to the present invention provides an improved production of solid dosage forms of desmopressin.

Description

PHARMACEUTICAL COMPOSITION AS SOLID DOSAGE FORM AND METHOD FOR MANUFACTURING THEREOF
Field of the Invention
The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof . Technical Background
Desmopressin, also known as dDAVP, is the therapeutically active ingredient (as its acetate salt) in the pharmaceutical product Minirin®, which is marketed inter alia as a nasal spray and a tablet formulation.
Desmopressin is primarily used in the treatment of primary nocturnal enuresis, i.e. bedwetting, in children, but it is approved also for the treatment of nocturia and diabetes insipidus. The first market introduction of the tablet formulation was in Sweden in 1987.
In short, a solid dosage form such as a tablet formulation is typically manufactured by compression of a suitable granulate to the desired solid dosage form, where the granulate is composed of the required constituents as a mixture of solid particles. Typical such particles are the therapeutically active ingredient, various excipients (fillers) , disintegrating agents, lubricants and binders, optionally together e . g. with flavoring agent, preservative and/or colorant. The commercially available Minirin® tablet is prepared according to this general protocol, and the tablet was first disclosed as set forth in the patent US 5 047 398, the teachings of which are incorporated herein by reference. For a comprehensive overview of pharmaceutical tablet manufacturing, see nTableting" (by N.A. Armstrong) in "Pharmaceutics - The science of dosage form design" , pp 647-668; Ed. M.E. Aulton, Churchill Livingstone, Edinburgh, London, Melbourne and New York, 1988, the entire teachings of which are incorporated herein by reference .
The Minirin® tablet that is currently marketed, and thus produced in industrial scale, consists of the thera- peutically active ingredient desmopressin together with potato starch and lactose as excipients, and a suitable amount of binder and lubricant, respectively.
In any tablet compression of a granulate composed of a mixture of solid particles there is a general need to perform the compressing operation at the highest possible speed while at the same time minimising machine wear and obtaining tablets of a quality that meets the regulatory demands of all relevant territories. Disclosure of the Invention It has now been discovered that a certain dimension of the excipient particles unexpectedly provides a substantial improvement on the speed of the manufacturing process, while both machine wear and tablet quality remain substantially unaltered compared to the industrial manufacturing process hitherto used. In essence, the dimension in question seems to affect the flowability of particles and granulate in such a manner that it provides an improved overall capacity, and hence speed, in the manufacturing process for the desmopressin tablet formulation.
More specifically, the present invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein at least one of said excipient, diluent and carrier is a substance selected from a monosaccharide, disaccharide, oligosac- charide and a polysaccharide, wherein the said substance has an average particle size in the range of from 60 to 1 000 μm. In those embodiments where there is a mixture of at least two of the aforementioned types of saccharides, at least one of them must accordingly be within the specified particle size range of the present invention. In many cases the terms excipient, diluent and carrier can be used interchangeably, and they may even refer to one and the same substance, or to a mixture of similar such substances. The proper use and understanding of these terms is self-explanatory and lies well within the ability of a person skilled in the art of pharmaceutical formulation.
The pharmaceutical composition according to the present invention may optionally comprise at least one additive selected from a disintegrating agent, lubricant, binder, flavoring agent, preservative, colorant and a mixture thereof. Where considered suitable also other additives may be included. Representative examples of disintegrating agents, lubricants ( e . g. magnesium stearate) , binders ( e . g. Kollidon® 25, BASF) , flavoring agents, preservatives and colorants, and suitable mixtures thereof, as well as any other conventional additive that may be considered by a person skilled in the art practising the present invention, can be found in "Handbook of Pharmaceutical Excipients" ; Ed. A.H. Kibbe, 3rd Ed. , American Pharmaceutical Association, USA and
Pharmaceutical Press UK, 2000, the teachings of which are incorporated herein by reference. As an example, also applicable in the practising of the present invention, it can be mentioned that typical amounts of lubricants and binders are in the order of less than 6 percent by weight of the pharmaceutical composition.
As used herein, the expression oligosaccharide relates to a chain, with any degree of branching, of from three to ten monosaccharide units linked via glycoside bonds. Accordingly, as used herein, the expression polysaccharide relates to a chain, with any degree of branching, of at least eleven monosaccharide units linked via glycoside bonds. Synthetically modified derivatives and analogues of naturally occurring saccharides are also possible to use in the practising of the present invention. In the marketed tablet resulting from the hitherto used manufacturing process, the lactose particles (Pharmatose 150M provided by DMV, the Netherlands) have an average size of about 50 μm, as determined by an air jet sieve (provided by Alpine GmbH, DE) . That particle size does not provide a granulate that allows a compressing speed exceeding about 170 000 tablets per hour (h) . In contrast thereto, the process according to the present invention allows a compressing speed of up to about 250 000 tablets/h with the desired tablet quality and retained low level of wear on the tabletting machinery.
As further examples of an upper limit for said average particle size mention can be made of 900, 800, 700 and 600 μm. However, in a preferred embodiment of said pharmaceutical composition, said average particle size is in the range of from 70 to 500 μm. In another preferred embodiment, said average particle size is in the range of from 75 to 350 μm. In yet another preferred embodiment, said average particle size is in the range of from 100 to 200 μm. In a further preferred embodiment, said average particle size is in the range of from 120 to 180 μm. In the most preferred embodiment of the present invention, said average particle size is 140 μm (as measured by an air jet sieve) . The lactose particles sold as Pharmatose DCL 15, marketed by DMV in the Netherlands, are of this most preferred average particle size. Other particular embodiments may involve use of e . g. Pharmatose DCL 11, Pharmatose DCL 21 and Pharmatose DCL 40, all provided by the aforementioned DMV, which have an average particle size of 110, 150 and 165 μm, respectively.
According to the commercial provider the particle size distribution of Pharmatose DCL 15 is that essentially all particles have a size below 500 μm, whereas approximately 72% of the particles have a size of from 75 to 350 μm.
In an air jet sieve measurement of particle size, air is drawn upwards, through a sieve, from a rotating slit so that material on the sieve is fluidised. At the same time a negative pressure is applied to the bottom of the sieve which removes fine particles to a collecting device. Size analyses and determination of average particle size are performed by removal of particles from the fine end of the size distribution by using single sieves consecutively. See also "Particle Size Measurement" , 5th Ed., p 178, vol. 1; T. Allen, Chapman & Hall, London, UK, 1997, for more details on this. For a person skilled in the art, the size measurement as such is thus of conventional character.
Accordingly, it is preferred that said substance is a disaccharide, preferably lactose, and more preferably lactose-α-monohydrate . As said polysaccharide, starch is preferred, and of the many available starches, potato starch is the most preferred. As examples of potato starches mention can be made of Pharma M20, Pharma M14 (provided by KMC, DK) and AmylSolVat (provided by Lyckeby Starkelse AB, SE) . In a preferred embodiment, both said disaccharide and polysaccharide are present in the pharmaceutical composition. In that particular embodiment, the weight ratio between said disaccharide and polysaccharide is typically from 100:1 to 1:100, preferably from 10:1 to 1:10, and more preferably from 2:1 to 1:2.
The total combined amount of said excipient, diluent and carrier is usually from 5 to 99, preferably from 50 to 99, percent by weight of the pharmaceutical composition, the balance up to 100% being the therapeutically active ingredient optionally together with the aforementioned additives, where the latter is preferably lubricant and binder. The pharmaceutical composition as a solid dosage form according to the present invention is typically a perorally available tablet. As an alternative non- limiting embodiment, the said tablet may be adapted for oral, including buccal and/or sublingual, administration. The composition typically comprises desmopressin acetate in an amount of from 20 to 600 μg per unit of solid dosage form. As an example, a typical tablet containing 100 μg of desmopressin acetate is white, convex and oval (6.7 x 9.5 mm) with a thickness of 3-4 mm and a weight of 200 mg. As another example, a tablet containing 200 μg of desmopressin acetate is white, round (8 mm diameter) and convex with a thickness of 3-4 mm and a weight of 200 mg. Accordingly, a further aspect of the present invention relates to a method for the manufacturing of a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient, wherein said method comprises the steps of: i) mixing desmopressin and an excipient, diluent or carrier, or mixture thereof, optionally in the presence of a wetting agent, wherein at least one of said excipient, diluent and carrier is a substance selected from a monosaccharide, disaccharide, oligosaccharide and a polysaccharide, wherein said substance has an average particle size in the range of from 60 to 1 000 μm; ii) subjecting the resulting mixture to formation of a granulate, optionally in the presence of a wetting agent, suitable for compression into said solid dosage form; iii) optionally performing said mixing and/or formation of a granulate in the presence of at least one additive selected from a disintegrating agent, lubricant, binder, flavoring agent, preservative, colorant and a mixture thereof; iv) optionally drying said granulate; v) compressing said granulate into said solid dosage form. The method according to the present invention can as such, once the specific components are identified and included, be practised by using conventional equipment for the manufacturing of pharmaceutical formulations . A granulate suitable for compression into tablets typically has an average granulate size of at least about 100 μm. Discrete granules with a size above 2 mm are usually not transferred to the subsequent compressing step.
As non-limiting examples mention can be made of the following equipment for granulation: directly heated fluidised solid beds e . g. provided by GEA/Collette NV, BE (UltimaPro™ series) , Hϋttlin GmbH, DE (HDG series) ,
Diosna Dierks & Soehne GmbH, DE (VAC series) , Fluid' Air Inc., US (Magnaflo® series) and Vector Corp., US (GMX series) ; indirect conduction moving solids bed, including paddle systems, rotary systems and agitation systems, which are e . g. provided by Jaygo Inc., US (JRB and
Novamix series), Paul O. Abbe Inc., US (Rota-Cone, Rota- U, Rota Blade, Cylindrical Ribbon/Paddle, Plow and Sigma- blade series) , Forberg A/S, NO (Forberg II series) , Gemco Inc., US (D/3 Double Cone, V-Shape and Slant-Cone series), LittlefordDay Inc., US (Double Arm, Day Nauta and Daymax series), Patterson-Kelly, Harsco Corp., US (P- K Solids Processor® series) , Diosna as above (CCS and VAC series) , Romaco Zanchetta SpA, IT (Roto E, Roto D and Roto P series) and L.B. Bohle Maschinen und Verfahren GmbH, DE (Granumator GMA and Vagumator VMA series) ;
The aforementioned equipment in general also provides drying of the prepared granules.
As indicated above, further examples of an upper limit for said average particle size are 900, 800, 700 and 600 μm. In a preferred embodiment of the method of the present invention, said average particle size is in the range of from 70 to 500 μm. In another preferred embodiment, said average particle size is in the range of from 75 to 350 μm. In yet another preferred embodiment, said average particle size is in the range of from 100 to 200 μm. In a further preferred embodiment, said average particle size is in the range of from 120 to 180 μm. In the most preferred embodiment of the present invention, said average particle size is 140 μm. The lactose particles sold as Pharmatose DCL 15, marketed by DMV in the Netherlands, are of this most preferred average particle size. Other possible embodiments of the present method may involve the aforementioned variants of Pharmatose DCL (vide supra) .
It is accordingly preferred that said substance is a disaccharide, preferably lactose, and more preferably lactose-α-monohydrate. Said monosaccharide may also be D- mannitol, D-sorbitol or xylitol or a mixture thereof.
Said polysaccharide is preferably a starch, and more preferably potato starch. Preferred particular potato starches are the same as those mentioned above. In the method according to the present invention, the manufactured solid dosage form is typically a perorally available tablet. Where desired, it may also be in a form and/or composition adapted for oromucosal administration. Preferred examples of the latter are buccal and/or sublingual administration. Examples of tablet compressing equipment suitable for the practising of the present invention are rotary presses provided by Elizabeth-Hata International, US (HT series) , Courtoy NV, BE (R090F, R100M, R190FT, R290FT, R292F and R233 series) , Vector Corp., US (2000, 200 and Magna series), Fette
GmbH, DE (Hightech, Medium, Special and WIP series) , Manesty, UK (Xpress, Diamond and Value series) and Kilian & Co. GmbH, DE (S, T, E, RX and KTS series) .
In a preferred embodiment of the present inventive method said steps of mixing and formation of granulate are performed in a single integrated machinery that is adapted for such a "one-pot", i . e . combined, process. An example of such integrated machinery, alternatively denoted one-pot (single pot) equipment, is the FT series, provided by Forberg A/S, Norway.
It is preferred that where used, said wetting agent is selected from water and a mixture of water and an alcohol, preferably ethanol . A water/ethanol 1:3 mixture is typically used, albeit many other combinations are also possible.
As indicated above, it is preferred that said resulting mixture is subjected to formation of a granulate with an average granulate size of a least 100 μm, preferably in the range of from 100 μm to 2 mm.
In a preferred embodiment of the method, both said disaccharide and polysaccharide are present in the mixing step. The weight ratio between said disaccharide and polysaccharide is then typically from 100:1 to 1:100, preferably from 10:1 to 1:10, and more preferably from 2:1 to 1:2.
The method is preferably performed in such a manner that the total combined amount of said excipient, diluent and carrier is from 5 to 99, preferably from 50 to 99, percent by weight of the pharmaceutical composition. In the most preferred embodiment, desmopressin acetate is used and mixed with said excipient, diluent and/or carrier in an amount that eventually provides from 20 to 600 μg of desmopressin acetate per unit of solid dosage form (see above and the experimental part for examples of a tablet) .
In a further aspect, the present invention also relates to a pharmaceutical composition as a solid dosage form that is obtainable by the novel method as defined above, both in general and as outlined in the specific embodiments .
In order to substantiate and illustrate the present invention in more detail, the following example is provided. It shall not be construed as a limitation of how the invention may be practised. Example
Example 1: Preparation of solid dosage form of dDAVP Desmopressin acetate (100 or 200 g; provided by PolyPeptide Laboratories AB, SE) , polyvinyl pyrrolidone (PVP) as binder (1,84 kg; Kollidon® 25 provided by BASF GmbH, DE) and granulation liquid (water/ethanol 1:3 mixture) are combined in a vessel and mixed at room temperature until a clear solution is achieved. The potato starch (77 kg, average particle size about 40-50 μm according to laser diffraction measurements;
AmylSolVat provided by Lyckeby Starkelse AB, SE) , is weighed and sieved through a 2 mm sieve. Lactose (120 kg, DCL 15 provided by DMV NV, NL; see above for the details of this product) is weighed and loaded together with the starch into a single pot mixer (FT-350; provided by Forberg A/S, NO) and mixed therein. The granulation liquid solution is then sprayed onto the powder mixture, after which the moist granulate is dried with warm air (150°C) , all with continued mixing. The dried granulate is then sieved (2 mm) and transferred to a double cone mixer. Magnesium stearate (max 1.0 kg; provided by Peter Greven NV, NL) is then weighed in, sieved (1 mm) and transferred to the double cone mixer for final mixing. Tablets are then compressed from the resulting mixture by using a conventional rotary tablet compression machine (Kilian S-250) , whereby a compressing speed of about 250 000 tablets/h is attainable with adequate tablet quality and low machine wear. A tablet of adequate quality has a smooth surface without scratches or chipped edges, and it shows no tendencies to lamination (so- called capping) .
The process is typically adapted to provide a tablet containing 100 or 200 μg of desmopressin acetate with the aforementioned appearance, dimension and weight.

Claims

1. A pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein at least one of said excipient, diluent and carrier is a substance selected from a monosaccharide, disaccharide, oligosaccharide and a polysaccharide, wherein the said substance has an average particle size in the range of from 60 to 1 000 μm.
2. A pharmaceutical composition according to claim 1, wherein said average particle size is in the range of from 70 to 500 μm.
3. A pharmaceutical composition according to any one of claims 1-2, wherein said average particle size is in the range of from 75 to 350 μm.
4. A pharmaceutical composition according to any one of claims 1-3, wherein said average particle size is in the range of from 100 to 200 μm.
5. A pharmaceutical composition according to any one of claims 1-4, wherein said average particle size is in the range of from 120 to 180 μm.
6. A pharmaceutical composition according to any one of claims 1-5, wherein said substance is a disaccharide, preferably lactose, and more preferably lactose-α- monohydrate .
7. A pharmaceutical composition according to any one of claims 1-6, wherein said polysaccharide is a starch, preferably potato starch.
8. A pharmaceutical composition according to any one of claims 1-7, wherein both said disaccharide and polysaccharide are present .
9. A pharmaceutical composition according to claim
8, wherein the weight ratio between said disaccharide and polysaccharide is from 100:1 to 1:100, preferably from 10:1 to 1:10, and more preferably from 2:1 to 1:2.
10. A pharmaceutical composition according to any one of claims 1-9, wherein the total combined amount of said excipient, diluent and carrier is from 5 to 99, preferably from 50 to 99, percent by weight of the pharmaceutical composition.
11. A pharmaceutical composition according to any one of claims 1-10, wherein said solid dosage form is a perorally available tablet that is optionally adapted for oromucosal, preferably buccal and/or sublingual, administration.
12. A pharmaceutical composition according to any one of claims 1-11, which comprises desmopressin acetate in an amount of from 20 to 600 μg per unit of solid dosage form.
13. A method for the manufacturing of a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient, wherein said method comprises the steps of: i) mixing desmopressin and an excipient, diluent or carrier, or mixture thereof, optionally in the presence of a wetting agent, wherein at least one of said excipient, diluent and carrier is a substance selected from a monosaccharide, disaccharide, oligosaccharide and a polysaccharide, wherein said substance has an average particle size in the range of from 60 to 1 000 μm; ii) subjecting the resulting mixture to formation of a granulate, optionally in the presence of a wetting agent, suitable for compression into said solid dosage form; iii) optionally performing said mixing and/or forma- tion of a granulate in the presence of at least one additive selected from a disintegrating agent, lubricant, binder, flavoring agent, preservative, colorant and a mixture thereof; iv) optionally drying said granulate; v) compressing said granulate into said solid dosage form.
14. A method according to claim 13, wherein said average particle size is in the range of from 70 to 500 μm.
15. A method according to any one of claims 13-14, wherein said average particle size is in the range of from 75 to 350 μm.
16. A method according to any one of claims 13-15, wherein said average particle size is in the range of from 100 to 200 μm.
17. A method according to any one of claims 13-16, wherein said average particle size is in the range of from 120 to 180 μm.
18. A method according to any one of claims 13-17, wherein said substance is a disaccharide, preferably lactose, and more preferably lactose-α-monohydrate.
19. A method according to any one of claims 13-18, wherein said polysaccharide is a starch, preferably potato starch.
20. A method according to any one of claims 13-19, wherein said solid dosage form is a perorally available tablet that is optionally adapted for oromucosal, preferably buccal and/or sublingual, administration.
21. A method according to any one of claims 13-20, wherein said steps of mixing and formation of a granulate are performed in a single integrated machinery that is adapted for such a combined process.
22. A method according to any one of claims 13-21, wherein said wetting agent is selected from water and a mixture of water and an alcohol, preferably ethanol .
23. A method according to any one of claims 13-22, wherein said resulting mixture is subjected to formation of a granulate with an average granulate size of a least 100 μm, preferably in the range of from 100 μm to 2 mm.
24. A method according to any one of claims 13-23, wherein both said disaccharide and polysaccharide are present in the mixing step.
25. A method according to claim 24, wherein the weight ratio between said disaccharide and polysaccharide is from 100:1 to 1:100, preferably from 10:1 to 1:10, and more preferably from 2:1 to 1:2.
26. A method according to any one of claims 13-25, wherein the total combined amount of said excipient, diluent and carrier is from 5 to 99 , preferably from 50 to 99, percent by weight of the pharmaceutical composition.
27. A method according to any one of claims 13-26, wherein desmopressin acetate is used and mixed with the excipient, diluent or carrier in an amount that provides from 20 to 600 μg of desmopressin acetate per unit of solid dosage form.
28. A pharmaceutical composition as a solid dosage form that is obtainable by a method as defined in any one of claims 13-27.
EP04730504A 2003-04-30 2004-04-30 Solid dosage form comprising desmopressin Withdrawn EP1670439A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04730504A EP1670439A2 (en) 2003-04-30 2004-04-30 Solid dosage form comprising desmopressin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03009659A EP1473029B1 (en) 2003-04-30 2003-04-30 Solid dosage form comprising desmopressin
PCT/EP2004/004597 WO2004096181A2 (en) 2003-04-30 2004-04-30 Solid dosage form comprising desmopressin
EP04730504A EP1670439A2 (en) 2003-04-30 2004-04-30 Solid dosage form comprising desmopressin

Publications (1)

Publication Number Publication Date
EP1670439A2 true EP1670439A2 (en) 2006-06-21

Family

ID=32981781

Family Applications (2)

Application Number Title Priority Date Filing Date
EP03009659A Expired - Lifetime EP1473029B1 (en) 2003-04-30 2003-04-30 Solid dosage form comprising desmopressin
EP04730504A Withdrawn EP1670439A2 (en) 2003-04-30 2004-04-30 Solid dosage form comprising desmopressin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP03009659A Expired - Lifetime EP1473029B1 (en) 2003-04-30 2003-04-30 Solid dosage form comprising desmopressin

Country Status (18)

Country Link
EP (2) EP1473029B1 (en)
JP (1) JP4597124B2 (en)
KR (1) KR100766455B1 (en)
CN (1) CN100438857C (en)
AT (1) ATE291419T1 (en)
AU (1) AU2004233596B2 (en)
CA (1) CA2486833C (en)
DE (1) DE60300414T2 (en)
DK (1) DK1473029T3 (en)
ES (1) ES2236640T3 (en)
MX (1) MXPA05011591A (en)
NO (1) NO331205B1 (en)
NZ (1) NZ542653A (en)
PL (1) PL211799B1 (en)
PT (1) PT1473029E (en)
RU (1) RU2290945C2 (en)
SI (1) SI1473029T1 (en)
WO (1) WO2004096181A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
EP1500390B1 (en) * 2003-07-25 2005-08-17 Ferring B.V. Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof
CA2490601C (en) * 2003-12-29 2006-05-02 Ferring B.V. Method for preparing solid dosage form of desmopressin
ES2319054B1 (en) 2007-08-06 2010-02-12 Gp Pharm S.A. ORAL PHARMACEUTICAL COMPOSITION OF DESMOPRESINA.
CN102423485B (en) * 2011-12-08 2014-08-06 赵联华 Oral composition containing desmopressin acetate and preparation method for oral composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8306367L (en) * 1983-11-18 1985-05-19 Ferring Ab ANTIDIURETICALLY EFFECTIVE PHARMACEUTICAL PREPARATION
SE9400918L (en) * 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabilized composition for oral administration of peptides
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US6210699B1 (en) * 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
JP2001139461A (en) * 1999-11-10 2001-05-22 Ohta Pharmaceut Co Ltd Quickly collapsable tablet
JP4596586B2 (en) * 2000-01-27 2010-12-08 旭化成ケミカルズ株式会社 Trehalose particles
KR100530546B1 (en) * 2001-07-27 2005-11-23 아스텔라스세이야쿠 가부시키가이샤 Composition Comprising Sustained-Release Fine Particles for Quick-Disintegrating Tablets in the Buccal Cavity and Manufacturing Method Thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004096181A2 *

Also Published As

Publication number Publication date
PL211799B1 (en) 2012-06-29
NO331205B1 (en) 2011-10-31
DK1473029T3 (en) 2005-04-18
CN1780608A (en) 2006-05-31
MXPA05011591A (en) 2005-12-15
WO2004096181A2 (en) 2004-11-11
ES2236640T3 (en) 2005-07-16
EP1473029B1 (en) 2005-03-23
NO20055016L (en) 2005-10-27
RU2005131494A (en) 2006-03-20
CN100438857C (en) 2008-12-03
SI1473029T1 (en) 2005-10-31
KR20060012592A (en) 2006-02-08
NZ542653A (en) 2008-04-30
AU2004233596A1 (en) 2004-11-11
RU2290945C2 (en) 2007-01-10
WO2004096181A3 (en) 2004-12-23
DE60300414D1 (en) 2005-04-28
EP1473029A1 (en) 2004-11-03
PL379703A1 (en) 2006-11-13
AU2004233596B2 (en) 2010-04-08
CA2486833C (en) 2005-08-02
ATE291419T1 (en) 2005-04-15
PT1473029E (en) 2005-05-31
CA2486833A1 (en) 2004-11-11
KR100766455B1 (en) 2007-10-15
JP4597124B2 (en) 2010-12-15
JP2006524663A (en) 2006-11-02
DE60300414T2 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
US20060252696A1 (en) Pharmaceutical composition as solid dosage form and method for manufacturing thereof
US20110033535A1 (en) Pharmaceutical composition as solid dosage form and method for manufacturing thereof
EP1500390B1 (en) Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof
EP1829532B1 (en) Stable solid dosage form comprising desmopressin
EP1473029B1 (en) Solid dosage form comprising desmopressin
CA2584456C (en) Composition comprising desmopressin
IL167612A (en) Method for manufacturing a pharmaceutical composition as solid dosage form comprising desmopressin acetate as a therapeutically active agent
CA2511353A1 (en) Solid dosage form comprising desmopressin and method for manufacturing thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060307

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

D17P Request for examination filed (deleted)
R17P Request for examination filed (corrected)

Effective date: 20060307

RAX Requested extension states of the european patent have changed

Extension state: MK

Payment date: 20060307

Extension state: LV

Payment date: 20060307

Extension state: LT

Payment date: 20060307

Extension state: HR

Payment date: 20060307

Extension state: AL

Payment date: 20060307

17Q First examination report despatched

Effective date: 20060718

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070131

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230513